174 related articles for article (PubMed ID: 32053044)
1. Assessment of efficacy of Oseltamivir-Azithromycin combination therapy in prevention of Influenza-A (H1N1)pdm09 infection complications and rapidity of symptoms relief.
Ishaqui AA; Khan AH; Sulaiman SAS; Alsultan MT; Khan I; Naqvi AA
Expert Rev Respir Med; 2020 May; 14(5):533-541. PubMed ID: 32053044
[No Abstract] [Full Text] [Related]
2. Assessment of Antiviral combination therapy with Cephalosporin antibiotic for prevention of severe Influenza-A (H1N1)pdm09 infection associated secondary bacterial infection and other complications.
Ishaqui AA; Khan AH; Syed Sulaiman SA; Alsultan M; Khan I
Pak J Pharm Sci; 2020 Jul; 33(4(Supplementary)):1763-1770. PubMed ID: 33612459
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy assessment of antiviral alone and antiviral-antibiotic combination in prevention of influenza-B infection associated complications.
Ishaqui A; Hayat Khan A; Sulaiman SAS; Taher Alsultan M; Khan I
Expert Rev Anti Infect Ther; 2021 Sep; 19(9):1165-1173. PubMed ID: 33567928
[TBL] [Abstract][Full Text] [Related]
4. Efficacy comparison of oseltamivir alone and oseltamivir-antibiotic combination for early resolution of symptoms of severe influenza-A and influenza-B hospitalized patients.
Ishaqui AA; Khan AH; Sulaiman SA; Alsultan M; Khan I
Saudi Med J; 2020 Sep; 41(9):1015-1021. PubMed ID: 32893285
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza: a multicenter, open-label, randomized study.
Kakeya H; Seki M; Izumikawa K; Kosai K; Morinaga Y; Kurihara S; Nakamura S; Imamura Y; Miyazaki T; Tsukamoto M; Yanagihara K; Tashiro T; Kohno S
PLoS One; 2014; 9(3):e91293. PubMed ID: 24632748
[TBL] [Abstract][Full Text] [Related]
6. Assessment of antiviral and antibiotic combination treatment in influenza-A H1N1 induced acute kidney injury among hospitalized patients.
Ishaqui AA; Khan AH; Syed Sulaiman SA; Alsultan MT; Khan I; Al Nami H
Pak J Pharm Sci; 2019 May; 32(3 (Supplementary)):1225-1233. PubMed ID: 31303595
[TBL] [Abstract][Full Text] [Related]
7. The combination of oseltamivir with azithromycin does not show additional benefits over oseltamivir monotherapy in mice infected with influenza A(H1N1)pdm2009 virus.
Fage C; Pizzorno A; Rhéaume C; Abed Y; Boivin G
J Med Virol; 2017 Dec; 89(12):2239-2243. PubMed ID: 28792077
[TBL] [Abstract][Full Text] [Related]
8. Timing of oseltamivir administration and outcomes in hospitalized adults with pandemic 2009 influenza A(H1N1) virus infection.
Viasus D; Paño-Pardo JR; Pachón J; Riera M; López-Medrano F; Payeras A; Fariñas MC; Moreno A; Rodríguez-Baño J; Oteo JA; Ortega L; Torre-Cisneros J; Segura F; Carratalà J;
Chest; 2011 Oct; 140(4):1025-1032. PubMed ID: 21415133
[TBL] [Abstract][Full Text] [Related]
9. Triple-combination antiviral drug for pandemic H1N1 influenza virus infection in critically ill patients on mechanical ventilation.
Kim WY; Young Suh G; Huh JW; Kim SH; Kim MJ; Kim YS; Kim HR; Ryu YJ; Han MS; Ko YG; Chon GR; Lee KH; Choi SH; Hong SB;
Antimicrob Agents Chemother; 2011 Dec; 55(12):5703-9. PubMed ID: 21968371
[TBL] [Abstract][Full Text] [Related]
10. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
[TBL] [Abstract][Full Text] [Related]
11. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China.
Cao B; Li XW; Mao Y; Wang J; Lu HZ; Chen YS; Liang ZA; Liang L; Zhang SJ; Zhang B; Gu L; Lu LH; Wang DY; Wang C;
N Engl J Med; 2009 Dec; 361(26):2507-17. PubMed ID: 20007555
[TBL] [Abstract][Full Text] [Related]
12. A multicenter evaluation of pandemic influenza A/H1N1 in hematopoietic stem cell transplant recipients.
Reid G; Huprikar S; Patel G; Razonable RR; Mossad S; Levi M; Gregg K; Shoham S; Humar A; Adams W; Kumar D
Transpl Infect Dis; 2013 Oct; 15(5):487-92. PubMed ID: 23890293
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial.
Hung IFN; To KKW; Chan JFW; Cheng VCC; Liu KSH; Tam A; Chan TC; Zhang AJ; Li P; Wong TL; Zhang R; Cheung MKS; Leung W; Lau JYN; Fok M; Chen H; Chan KH; Yuen KY
Chest; 2017 May; 151(5):1069-1080. PubMed ID: 27884765
[TBL] [Abstract][Full Text] [Related]
14. Virus susceptibility and clinical effectiveness of anti-influenza drugs during the 2010-2011 influenza season in Russia.
Leneva IA; Burtseva EI; Yatsyshina SB; Fedyakina IT; Kirillova ES; Selkova EP; Osipova E; Maleev VV
Int J Infect Dis; 2016 Feb; 43():77-84. PubMed ID: 26775570
[TBL] [Abstract][Full Text] [Related]
15. Degree of adherence to recommended antiviral treatment during the pandemic and post-pandemic periods of influenza A(H1N1)pdm09 in 148 intensive care units in Spain.
Canadell L; Martín-Loeches I; Díaz E; Trefler S; Grau S; Yebenes JC; Almirall J; Olona M; Sureda F; Blanquer J; Rodriguez A;
Med Intensiva; 2015 May; 39(4):222-33. PubMed ID: 25107582
[TBL] [Abstract][Full Text] [Related]
16. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial.
Wang C; Cao B; Liu QQ; Zou ZQ; Liang ZA; Gu L; Dong JP; Liang LR; Li XW; Hu K; He XS; Sun YH; An Y; Yang T; Cao ZX; Guo YM; Wen XM; Wang YG; Liu YL; Jiang LD
Ann Intern Med; 2011 Aug; 155(4):217-25. PubMed ID: 21844547
[TBL] [Abstract][Full Text] [Related]
17. Frequency of oseltamivir resistance in Sydney, during the Newcastle outbreak of community transmitted oseltamivir-resistant influenza A(H1N1)pdm09 virus, Australia, June to August 2011.
Wang B; Taylor J; Ratnamohan M; McPhie K; Kesson A; Dixit R; Booy R; Hurt A; Saksena N; Dwyer DE
Euro Surveill; 2012 Jul; 17(27):. PubMed ID: 22790606
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
[TBL] [Abstract][Full Text] [Related]
19. Antiviral treatment and virological monitoring of oseltamivir-resistant influenza virus A(H1N1)pdm09 in a patient with chronic B lymphocytic leukemia.
Salata C; Sgarabotto D; Del Vecchio C; Solimbergo E; Marini G; Nicolè S; Franchin E; Parolin C; Calistri A; Palù G
J Infect Chemother; 2019 Jul; 25(7):543-546. PubMed ID: 31014561
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of clarithromycin-naproxen-oseltamivir combination therapy versus oseltamivir alone in hospitalized pediatric influenza patients.
Lee CW; Tai YL; Huang LM; Chi H; Huang FY; Chiu NC; Huang CY; Tu YH; Wang JY; Huang DT
J Microbiol Immunol Infect; 2021 Oct; 54(5):876-884. PubMed ID: 32978076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
